D
Xeris Biopharma Holdings, Inc. XERS
$4.88 -$0.27-5.24%
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
52-Week Range
P/E (TTM)
--
EPS (TTM)
Weiss Ratings XERS - NASDAQ Click to
Compare
Click to
Compare
Click to
Compare
Rating D
Reward Index Very Weak
Risk Index Weak
Risk Grade D
Reward Grade E
Rating Factors XERS - NASDAQ Click to
Compare
Click to
Compare
Click to
Compare
Dividend Index --
Growth Index Good
Efficiency Index Very Weak
Solvency Index Fair
Total Return Index Fair
Volatility Index Weak
Beta / Standard Deviation XERS - NASDAQ Click to
Compare
Click to
Compare
Click to
Compare
Beta 1.33
Price History XERS - NASDAQ Click to
Compare
Click to
Compare
Click to
Compare
7-Day Total Return -16.87%
30-Day Total Return 22.92%
60-Day Total Return 37.85%
90-Day Total Return 59.48%
Year to Date Total Return 41.04%
1-Year Total Return 134.62%
2-Year Total Return 168.13%
3-Year Total Return 84.85%
5-Year Total Return --
52-Week High % Change -15.16%
52-Week Low % Change 204.73%
Price XERS - NASDAQ Click to
Compare
Click to
Compare
Click to
Compare
52-Week High Price $6.07
52-Week Low Price $1.69
52-Week Low Price (Date) Apr 19, 2024
52-Week High Price (Date) Mar 26, 2025
Valuation XERS - NASDAQ Click to
Compare
Click to
Compare
Click to
Compare
Market Cap 792.79M
Enterprise Value 992.62M
Price/Earnings (TTM) --
Earnings Per Share (TTM) -0.38
Earnings Per Share Growth -16.87%
Price/Earnings To Growth --
Price/Sales (TTM) 3.78
Price/Book (Q) -25.98
Enterprise Value/Revenue (TTM) 4.89
Price $4.88
Enterprise Value/EBITDA (TTM) -64.14
Enterprise Value/EBIT -36.03
Market Cap Category Small Cap
Dividends and Shares XERS - NASDAQ Click to
Compare
Click to
Compare
Click to
Compare
Shares Outstanding 149.09M
Dividend Yield --
Div. Per Share (Most Recent) --
Dividend Per Share (TTM) --
Payout Ratio (TTM) --
Dividend Per Share (Most Recent) --
Company Info XERS - NASDAQ Click to
Compare
Click to
Compare
Click to
Compare
Phone Number 844 445 5704
Address 1375 West Fulton Street Chicago, IL 60607
Website www.xerispharma.com
Country United States
Year Founded 2005
Profitability XERS - NASDAQ Click to
Compare
Click to
Compare
Click to
Compare
Operating Margin (TTM) -13.56%
Profit Margin -27.00%
Management Effectiveness XERS - NASDAQ Click to
Compare
Click to
Compare
Click to
Compare
Return on Assets -5.33%
Return on Equity --
Income Statement XERS - NASDAQ Click to
Compare
Click to
Compare
Click to
Compare
Revenue (TTM) 203.07M
Total Revenue (TTM) 203.07M
Revenue Per Share $1.36
Gross Profit (TTM) 166.24M
EBITDA (TTM) -15.48M
EBIT (TTM) -27.55M
Net Income (TTM) -54.84M
Net Income Avl. to Common (TTM) -54.84M
Total Revenue Growth (Q YOY) 35.39%
Earnings Growth (Q YOY) 61.81%
EPS Diluted (TTM) -0.38
EPS Diluted Growth (Q YOY) 64.60%
Balance Sheet XERS - NASDAQ Click to
Compare
Click to
Compare
Click to
Compare
Cash and Short-Term Inv. (Q) 71.62M
Cash Per Share (Q) $0.48
Total Current Assets (Q) 167.66M
Total Preferred Equity (Q) --
Total Equity (Q) -29.62M
Current Ratio (Q) 1.669
Book Value Per Share (Q) -$0.20
Total Assets (Q) 323.06M
Total Current Liabilities (Q) 100.44M
Total Debt (Q) 271.45M
Total Liabilities (Q) 352.68M
Total Common Equity (Q) -29.62M
Cash Flow XERS - NASDAQ Click to
Compare
Click to
Compare
Click to
Compare
Cash from Investing (TTM) 4.88M
Cash from Financing (TTM) 36.17M
Net Change in Cash (TTM) 4.07M
Levered Free Cash Flow (TTM) -27.81M
Cash from Operations (TTM) -36.98M
Weiss Ratings